Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 82,600 shares, an increase of 58.2% from the August 15th total of 52,200 shares. Based on an average daily trading volume, of 362,500 shares, the days-to-cover ratio is presently 0.2 days.
Institutional Trading of Biomerica
Hedge funds have recently made changes to their positions in the stock. Perritt Capital Management Inc bought a new position in shares of Biomerica in the second quarter valued at $31,000. Fore Capital LLC raised its stake in Biomerica by 72.1% during the first quarter. Fore Capital LLC now owns 59,680 shares of the company’s stock worth $50,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Biomerica by 11.8% in the first quarter. Russell Investments Group Ltd. now owns 225,435 shares of the company’s stock worth $188,000 after purchasing an additional 23,872 shares in the last quarter. Institutional investors and hedge funds own 22.28% of the company’s stock.
Biomerica Stock Up 1.1 %
Shares of NASDAQ:BMRA traded up $0.00 during trading on Friday, reaching $0.31. 88,095 shares of the stock were exchanged, compared to its average volume of 242,408. Biomerica has a 12-month low of $0.24 and a 12-month high of $2.13. The firm’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.61.
Biomerica Company Profile
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
Featured Articles
- Five stocks we like better than Biomerica
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- ESG Stocks, What Investors Should Know
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- How is Compound Interest Calculated?
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.